Media ReleasesImmutep

View All Immutep News


Immutep to Present at Upcoming Industry Conferences

SYDNEY, AUSTRALIA – 26 February 2019 - Immutep Limited (ASX:IMM;NASDAQ: IMMP) (Immutep or the Company), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, today announced its participation in various upcoming industry conferences.

The Company will be presenting updated clinical data from the Phase I TACTI-mel trial in metastatic melanoma for its lead product candidate eftilagimod alpha (“efti” or “IMP321”) and new data relating to its pre-clinical product candidate, IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases, at industry conferences in March 2019.


For further information please download PDF attached:
Download this document